Native-like trimers of the SOSIP design are being developed as immunogens in human
immunodeficiency virus type 1 (HIV-1) vaccine development programs. These trimers …

Stabilized HIV-1 envelope glycoprotein trimers for vaccine u... : Current Opinion in HIV and
AIDS Stabilized HIV-1 envelope glycoprotein trimers for vaccine use : Current Opinion in HIV …

In the past 20 years, the mRNA vaccine technology has evolved from the first proof of
concept to the first licensed vaccine against emerging pandemics such as SARS-CoV-2 …

The display of native-like human immunodeficiency virus type 1 envelope (HIV-1 Env)
trimers on liposomes has gained wide attention over the last few years. Currently, available …

Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine
available against HIV-1. Currently, substantial efforts are devoted to the development of …

We covalently attached human immunodeficiency virus type 1 (HIV-1) Env SOSIP trimers to
iron oxide nanoparticles (IO-NPs) to create a particulate immunogen for neutralizing …

The development of effective vaccines is urgently needed to curb the spread of human
immunodeficiency virus type 1 (HIV-1). A major focal point of current HIV vaccine research is …

A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of
its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains …

Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated
35 million. During its 40‐year history, remarkable progress has been made on antiretroviral …

Native-like, soluble, recombinant SOSIP trimers of various designs and based on several
env genes of human immunodeficiency virus type 1 (HIV-1) are being tested as …